

## Recombinant Mouse CD30 Ligand/TNFSF8 Protein(Fc Tag)

Catalog Number: PDMM100135

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

Species	Mouse
Source	Mammalian-derived Mouse CD30 Ligand/TNFSF8 protein Gln68-Asp239, with an C-terminal Fc
Calculated MW	43.8 kDa
Observed MW	55-65 kDa
Accession	P32972
Bio-activity	Not validated for activity

### Properties

Purity	> 90% as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU/mg of the protein as determined by the LAL method
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with 5% Trehalose and 5% Mannitol.
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

### Data



SDS-PAGE analysis of Mouse CD30 Ligand/TNFSF8 proteins, 2 µg/lane of Recombinant Mouse CD30 Ligand/TNFSF8 proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 55-65 KD

### Background

### For Research Use Only

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases. 全称